193 related articles for article (PubMed ID: 18235392)
1. [Positron emission tomography in the diagnosis and follow up of non-small cell lung cancer].
Vaylet F; Rivière F; Le Floch H; Bonnichon A; Mairovitz A; Staub E; Bonardel G; Margery J; Mantzarides M; Marotel C; Foehrenbach H
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S35-9. PubMed ID: 18235392
[TBL] [Abstract][Full Text] [Related]
2. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer.
Pozo-Rodríguez F; Martín de Nicolás JL; Sánchez-Nistal MA; Maldonado A; García de Barajas S; Calero-García R; Pozo MA; Martín-Escribano P; Martín-García I; García-Lujan R; Lopez-Encuentra A; Arenas de Pablo A
J Clin Oncol; 2005 Nov; 23(33):8348-56. PubMed ID: 16219937
[TBL] [Abstract][Full Text] [Related]
5. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
Laking G; Price P
Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
[No Abstract] [Full Text] [Related]
6. [Positron emission tomography using 18F-fluorodeoxyglucose in the management of nonsmall cell lung cancers in 2006].
Vaylet F; Bonnichon A; Salles Y; Gontier E; Bonardel G; Lefloch H; Mairovitz A; Mantzarides M; Niang A; Marotel C; Foehrenbach H
Cancer Radiother; 2007; 11(1-2):16-22. PubMed ID: 17137819
[TBL] [Abstract][Full Text] [Related]
7. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review.
Mac Manus M; Hicks RJ
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1298-306. PubMed ID: 19028270
[No Abstract] [Full Text] [Related]
8. FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls.
Vansteenkiste JF
Lung Cancer; 2005 Feb; 47(2):151-3. PubMed ID: 15639713
[No Abstract] [Full Text] [Related]
9. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer.
Giaccone G
J Natl Cancer Inst; 2007 Dec; 99(23):1741-3. PubMed ID: 18042929
[No Abstract] [Full Text] [Related]
10. The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.
Bryant AS; Cerfolio RJ
J Thorac Cardiovasc Surg; 2006 Dec; 132(6):1363-8. PubMed ID: 17140957
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography imaging in nonsmall-cell lung cancer.
Erasmus JJ; Macapinlac HA; Swisher SG
Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
[TBL] [Abstract][Full Text] [Related]
12. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
[TBL] [Abstract][Full Text] [Related]
13. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
14. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
Vilstrup MH; Torigian DA
PET Clin; 2014 Oct; 9(4):391-420, v. PubMed ID: 26050944
[TBL] [Abstract][Full Text] [Related]
15. Lessons from the old masters: pragmatism or purity, FDG PET SUV, serum glucose and prediction of nodal status in non-small cell lung cancer.
Akhurst T
J Surg Oncol; 2006 Dec; 94(7):547-8. PubMed ID: 17111390
[No Abstract] [Full Text] [Related]
16. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
17. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Gong HY; Yu JM
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
[No Abstract] [Full Text] [Related]
18. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
Liu SW; Yu JM; Xing LG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
[TBL] [Abstract][Full Text] [Related]
19. Use of anthropometric factors in 18F-FDG PET bone marrow SUVs.
Thie JA
J Nucl Med; 2006 Nov; 47(11):1901-2; author reply 1902. PubMed ID: 17079825
[No Abstract] [Full Text] [Related]
20. Small bowel metastasis from lung cancer detected on FDG PET/CT.
Tulchinsky M; Coquia S; Wagner H
Clin Nucl Med; 2009 Jul; 34(7):446-8. PubMed ID: 19542953
[No Abstract] [Full Text] [Related]
[Next] [New Search]
